Abstract
Interferon’s (α and β), produced both by recombinant DNA technology as well as purified from natural sources, have been shown to be efficacious in treating certain cancers and viral diseases. Studies with γ-interferon have more recently been undertaken, and thus definition of their clinical utility is not yet as well defined. The treatment schedules usually involve multiple injections of the Interferon (IFN) over a period of several weeks to many months. Using such treatment regimens, the dose levels of the interferons needed to obtain efficacy can result in toxic side effects. For all these reasons, methods of increasing the ease of administration as well as the therapeutic ratio of interferons are warranted.
This is the Contribution #247 from the Institute of Bio-Organic Chemistry, Syntex Research.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allison, A.C. and Gregoriadis, G. (1974). Liposomes as immunological adjuvants. Nature 252: 252.
Amkraut, A.A., and Martins, A.B. (1984). Method for administering immunopotentiator. U.S. Patent #4,484,923.
Bonnern, E.M. and Spiegel, R.J. (1984). Interferon-α: current status and future promise. J. Bioi. Resp. Mod. 3: 580–598.
Borden, E.C. (1984). Progress toward therapeutic application of interferons, 1979-1983. Cancer, 54: 2770–2776.
Eppstein, D.A. (1986). Alternate delivery of interferons, In “Drug Targeting with Synthetic Systems,” NATO ASI Conference, 1985, Ed. G. Gregoriadis, Plenum Pub. Co. (in press).
Eppstein, D.A. and Felgner, P.L. (1987). Applications of liposome formulations for antimicrobial/antiviral therapy, in “Liposomes as Drug Carrriers: Trends and Progress,” Ed. G. Gregoriadis, John Wiley and Sons, LTD. (in press).
Eppstein, D.A., Marsh, Y.V., van der Pas, M.A., Felgner, P.L., and Schreiber, A.B. (1985). Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor. Proc. Natl. Acad. Sci. USA 82: 3688–3692.
Quesada, J.R., Reuben, J., Manning, J.T., Hersh, E.M., and Gutterman, J.U. (1984). Alpha interferon for induction of remission in hairy-cell leukemia. N. Eng. J. Med. 310: 15–18.
Quesada, J.R., Rios, A., Swanson, D., Trown, P. and Gutterman, J.U. (1985). Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 3: 1522–1528.
Sanders, L.M., Kent, J.S., McRae, G.I., Vickery, B.H., Tice, T.R., and Lewis, D.H. (1984). Controlled release of a luteinizing hormonereleasing hormone analog from poly (d,l-lactide-co-glycolide)-microspheres. J. Pharmaceut. Sci. 73: 1294–1297.
Schonfeld, A., Schattner, A., Crespi, M., Levavi, H., Shoham, J., Nitke, S., Wallach, D., Hahn, T., Yarden, O., Doerner, T., and Revel, M. (1984). Intramuscular human interferon-ß injections in treatment of condylomata acuminata. Lancet 1: 1038–1042.
Vance, J.C., Bart, B.J., Hansen, R.C., Reichman, R.C., McEwen, C., Hatch, K.D., Berman, B., and Tanner, D.J. (1986). Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch. Dermatol. 122: 272–277.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer Science+Business Media New York
About this chapter
Cite this chapter
Eppstein, D.A., van der Pas, M.A., Schryver, B.B., Felgner, P.L., Gloff, C.A., Soike, K.F. (1986). Controlled-Release and Localized Targeting of Interferons. In: Davis, S.S., Illum, L., Tomlinson, E. (eds) Delivery Systems for Peptide Drugs. NATO ASI Series, vol 125. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9960-6_24
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9960-6_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9962-0
Online ISBN: 978-1-4757-9960-6
eBook Packages: Springer Book Archive